pirtobrutinib
eli lilly
['bruin study', 'dlbcl', ' ofa ', 'fil,veral,12', 'pirto', 'pcnsl', 'leukemia', 'bruin', 'emergent ', 'valent ,(-prevalent),(-equivalent),(-bivalent)', 'valent ,(-prevalent)']
richter cohort in bruin #ash22
n=82 (wow!)
orr 52% crr 13%
mpfs 3.7 months, only 5 patients with response &gt;12m
very well tolerated (common theme in pirto studies)
i'm not particularly optimistic re btki in rs but if part of a multi-drug strategy pirto will likely add minimal tox 
Doc from Melbourne, Australia. Treats patients with blood cancers and researches new therapies. Loves family, immersive theatre and running.